Inne is a Berlin-based femtech company that builds a consumer medical device and app to track female reproductive hormones at home using a saliva-based “minilab,” primarily to help users predict ovulation, assess fertility and monitor reproductive health such as perimenopause and progesterone patterns[1][2].
High-Level Overview
- Mission: Inne’s stated mission is to empower women to make informed decisions about fertility and reproductive health by combining biochemistry and consumer technology into a seamless at‑home product[3][4].
- Investment philosophy / Key sectors / Impact (for an investment firm — not applicable): Inne is a portfolio company (femtech / digital health / consumer medical devices); it has raised venture funding including a Series A extension led by DSM Venturing and participation from Borski Fund, Calm Storm Ventures and prominent angel investors[1][4].
- Product, users, problem, growth (for the portfolio company): Inne builds the inne Minilab — a compact at‑home saliva biosensor that measures fertility hormones (notably progesterone and FSH in some reports) and pairs with an app that interprets results and predicts ovulation or menopause-related changes[1][3]. It serves menstruating people seeking natural fertility tracking, contraception alternatives, or insight into perimenopause, and addresses the problem of unreliable cycle predictions from apps alone by providing lab‑accurate hormone measurements at home[1][4]. The company launched commercially after lengthy R&D and stealth work in 2019, sold early units during COVID disruptions, and had raised ~€9–10M in follow‑on funding to scale production and features[2][1][4].
Origin Story
- Founding year and founders: Inne was founded in 2016 and is led by CEO & founder Eirini Rapti, who assembled a cross‑disciplinary team of scientists, designers and product people to build the device[1][3][4].
- How the idea emerged: Rapti describes a personal need for a modern, portable, science‑backed tool to collect hormonal data — replacing bulky, outdated hardware with a product that fits everyday life, which motivated multi‑year R&D to create a saliva-based minilab[3].
- Early traction / pivotal moments: Inne completed stealth R&D and prepared to launch in late 2019 but was disrupted by COVID‑19; despite that, the company circulated early devices (hundreds to low thousands) and used that period to refine operations and clinical rigor, later raising an additional Series A extension (~€9.3M / $10M) to expand production and features[2][1][4]. The company reports collecting over 100,000 hormone data points from users in Europe in its early stages[1].
Core Differentiators
- At‑home saliva biosensor: The inne Minilab is positioned as the first at‑home test to track fertility hormones via saliva, emphasizing convenience and non‑invasiveness compared with blood draws or clinic visits[3][4].
- Clinical and regulatory focus: Inne emphasizes performance evaluation studies, clinical trials and regulatory compliance (IVDR and medical device registration) to position the product as a medically credible consumer device[3].
- Product + app integration: Combines daily biochemical measurements with an app that interprets hormone trends to predict ovulation, fertility windows and perimenopausal signals, delivering actionable insights rather than raw test results[1][4].
- Design and user experience: The company stresses a compact, travel‑friendly form factor and consumer design sensibilities intended to fit modern lifestyles[3].
- Data foundation & team: A science‑led team (R&D scientists and data scientists) and an early dataset of hormonal measurements underpin its predictive models and product roadmap[1][3].
Role in the Broader Tech Landscape
- Trend alignment: Inne sits at the intersection of femtech, consumer diagnostics, and personalized health monitoring — trends that include at‑home testing (rapid growth since COVID), increased demand for women’s health solutions, and shifting regulatory attention to medical‑grade consumer devices[2][3].
- Timing and market forces: Rising consumer interest in reproductive autonomy, growing investment into femtech, and improving biosensor technology make the company’s offering more commercially viable now than a few years earlier; COVID forced a slower rollout but also accelerated acceptance of remote health tools[2][4].
- Ecosystem influence: By pursuing clinical validation and regulatory compliance for a consumer hormone tracker, Inne pushes the femtech sector toward higher scientific rigor and may raise expectations for medical credibility in direct‑to‑consumer reproductive health products[3][4].
Quick Take & Future Outlook
- What’s next: Inne plans to scale manufacturing and product features, expand geographic availability (including ambitions for U.S. entry), and extend use cases across fertility, contraception and broader reproductive health monitoring as it deploys additional funding and clinical evidence[2][4].
- Trends that will shape them: Regulatory guidance for consumer diagnostics, competition from app+lab hybrids and other at‑home biosensor startups, and consumer privacy/regulatory concerns around reproductive data will be major factors in Inne’s trajectory[2][3].
- How influence may evolve: If Inne succeeds in marrying robust clinical validation with a delightful consumer experience at scale, it could become a benchmark for medically credible femtech hardware and accelerate mainstream adoption of hormone‑based at‑home diagnostics, while also influencing clinical care pathways for fertility and perimenopause monitoring[3][4].
Quick take: Inne is a science‑first femtech hardware + software startup that matured through difficult early commercialization conditions, holds regulatory and clinical ambitions for an at‑home saliva minilab, and is positioned to push reproductive health monitoring toward more accurate, consumer‑accessible biochemical testing as it scales with venture backing[2][3][4].
